Blood Based Colorectal Cancer Screening Enters the Guidelines.

In August 2026, the American Cancer Society (ACS) made a landmark update: blood tests are now officially included as an option for colorectal cancer (CRC) screening. This shift follows the FDA’s 2024 approval of the first CRC screening blood test — a milestone that signals growing momentum for blood-based early detection technologies.

But the nuance matters.

While ACS added blood tests to the guideline, the organization is clear: these tests are not preferred. Colonoscopy, FIT, and multi-target stool DNA tests remain the gold standard because of their superior sensitivity and proven preventive impact. Blood-based screening is recommended only when patients decline all other established modalities.

For the IVD industry, this creates a fascinating strategic landscape. A New Door Opens — But Not All the Way.

Blood-based CRC screening offers undeniable advantages:

• Simple phlebotomy instead of stool collection

• Higher patient acceptance

• Potential for broader population reach

• Integration into routine primary care workflows

Yet ACS’s caution reflects the current performance gap: blood tests detect cancer, but less reliably at early stages, where screening has the greatest impact.

This tension — accessibility vs. sensitivity — is exactly where innovation will accelerate.

What This Means for Diagnostics Manufacturers?

The ACS update validates the category. It signals to investors, health systems, and payers that blood-based CRC screening is no longer hypothetical — it’s guideline-recognized.

But it also raises critical questions:

• How quickly will payers expand coverage?

• Will primary care adopt blood tests as a first-line conversation starter?

• How will stool-based test manufacturers respond competitively?

• What evidence will be required to elevate blood tests from “acceptable” to “preferred”?

Manufacturers developing methylation-based assays, multi-omic signatures, or circulating tumor DNA (ctDNA) platforms now have a clearer regulatory and clinical pathway — but also a higher bar to demonstrate value.

The ACS update is more than a guideline change— it signals that blood-based early detection is entering the mainstream conversation. Companies that understand the implications now will be best positioned to lead the next wave of innovation. If your organization is developing, investing in, or competing within the CRC screening ecosystem, GRN IVD Consulting can help you navigate the landscape with clarity, evidence-based insight, and strategic precision.